3,260 Shares in Veeva Systems Inc. (NYSE:VEEV) Bought by Murphy & Mullick Capital Management Corp

Murphy & Mullick Capital Management Corp bought a new position in shares of Veeva Systems Inc. (NYSE:VEEV) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,260 shares of the technology company’s stock, valued at approximately $685,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. raised its position in shares of Veeva Systems by 138.9% during the third quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock worth $457,366,000 after acquiring an additional 1,267,061 shares during the last quarter. JPMorgan Chase & Co. increased its position in Veeva Systems by 73.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,558,592 shares of the technology company’s stock valued at $536,972,000 after purchasing an additional 1,081,501 shares during the period. Wealthfront Advisers LLC raised its holdings in Veeva Systems by 29,760.5% during the 4th quarter. Wealthfront Advisers LLC now owns 1,048,700 shares of the technology company’s stock worth $220,489,000 after purchasing an additional 1,045,188 shares during the last quarter. FMR LLC lifted its position in shares of Veeva Systems by 25.7% in the 3rd quarter. FMR LLC now owns 2,981,244 shares of the technology company’s stock worth $625,674,000 after purchasing an additional 610,021 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Veeva Systems in the 4th quarter valued at $95,710,000. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Trading Up 0.6 %

Shares of Veeva Systems stock opened at $240.41 on Wednesday. The firm has a market capitalization of $39.03 billion, a P/E ratio of 59.36, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. The business’s fifty day simple moving average is $230.35 and its 200 day simple moving average is $222.59. Veeva Systems Inc. has a 12 month low of $170.25 and a 12 month high of $258.93.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Mizuho started coverage on shares of Veeva Systems in a report on Wednesday, December 4th. They issued an “outperform” rating and a $275.00 target price on the stock. Morgan Stanley boosted their price objective on Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research note on Thursday, March 6th. Stifel Nicolaus raised their target price on Veeva Systems from $240.00 to $272.00 and gave the stock a “buy” rating in a research note on Friday, December 6th. Piper Sandler boosted their price target on Veeva Systems from $280.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Finally, JPMorgan Chase & Co. increased their price target on Veeva Systems from $218.00 to $249.00 and gave the stock a “neutral” rating in a report on Thursday, March 20th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Veeva Systems has a consensus rating of “Moderate Buy” and a consensus target price of $256.52.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.